Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06518512 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Automated Vision Assessment and Impairment Detection Through Gaze Analysis in Wet AMD Patients

Study acronym: AVIGA2
StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site details revised
    • Publications: details revised at 10 of 10 entries
    v4
  2. Primary endpoint revised
    • Secondary endpoint revised
    v3
  3. Primary and study completion dates: Dec 2024 to Dec 2026
    • Secondary endpoints: details revised at 1 of 1 entry
    • Site details revised
    • Publications: details revised at 10 of 10 entries
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study aims to evaluate the Automated Vision Assessment and Impairment Detection through Gaze Analysis (AVIGA) system in the ability to detect and assess central vision dysfunction in a personalized, adaptive, objective, and automated way through eye gaze tracking in age-related macular degeneration (AMD). We also aim to develop a novel algorithm / scoring methodology for disease activity monitoring over time (delta-change). AVIGA visual risk prediction cut-off scores will be presented together with probabilities of occurrence of prespecified adverse clinical outcome.
Trial Details
NCT Number NCT06518512
Lead Sponsor Tan Tock Seng Hospital
Collaborators: Occutrack Medical Solutions Pte Ltd
Conditions
(from sponsor)		 Age-Related Macular Degeneration, Wet Age-related Macular Degeneration
Related terms Macular Degeneration
Enrollment 128 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov